Drug Profile
Research programme: Alzheimer's disease immunotherapy - Novartis
Latest Information Update: 22 May 2012
Price :
$50
*
At a glance
- Originator Novartis
- Class Cell therapies; Monoclonal antibodies
- Mechanism of Action Amyloid beta-protein inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 22 May 2012 No development reported - Preclinical for Alzheimer's disease in Switzerland (Parenteral)
- 19 Nov 2008 Preclinical trials in Alzheimer's disease in Switzerland (unspecified route)